# Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

> **NCT00445328** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 84 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Dalteparin (Fragmin)
- **DRUG:** Unfractionated heparin

## Key facts

- **NCT ID:** NCT00445328
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** See Detailed Description
- **Last updated:** 2009-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445328, "Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00445328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*